Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway

BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in type 2 diabetes therapy, has demonstrated protective effects in diabetic chronic kidney disease, in part due to its pleiotropic actions. However, its potential direct effects on the kidney are still not completely defined. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Civantos, Esther, Bosch, Enrique, Ramirez, Elisa, Zhenyukh, Olha, Egido, Jesús, Lorenzo, Oscar, Mas, Sebastián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473486/
https://www.ncbi.nlm.nih.gov/pubmed/28652790
http://dx.doi.org/10.2147/DMSO.S132537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473486/
https://www.ncbi.nlm.nih.gov/pubmed/28652790
http://dx.doi.org/10.2147/DMSO.S132537

Ejemplares similares